Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors

NCT04801095 is registered in ClinicalTrials.gov with Wellmarker Bio as lead sponsor.

NCT NCT04801095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors
Lead sponsor
Wellmarker Bio
Phase
Phase 1
Overall status
Unknown status
Start date
July 14, 2021
Completion date
August 8, 2025
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cholangiocarcinoma, colorectal cancer, head and neck cancer, lung cancer, metastatic solid tumor, pancreatic cancer